Advertisement
Canada markets closed
  • S&P/TSX

    21,978.18
    -138.52 (-0.63%)
     
  • S&P 500

    5,291.34
    +7.94 (+0.15%)
     
  • DOW

    38,711.29
    +140.29 (+0.36%)
     
  • CAD/USD

    0.7312
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    73.07
    -0.18 (-0.25%)
     
  • Bitcoin CAD

    97,117.45
    +2,738.70 (+2.90%)
     
  • CMC Crypto 200

    1,476.30
    +29.15 (+2.01%)
     
  • GOLD FUTURES

    2,345.80
    -1.60 (-0.07%)
     
  • RUSSELL 2000

    2,033.94
    -25.74 (-1.25%)
     
  • 10-Yr Bond

    4.3360
    -0.0660 (-1.50%)
     
  • NASDAQ futures

    18,723.50
    +22.50 (+0.12%)
     
  • VOLATILITY

    13.16
    +0.05 (+0.38%)
     
  • FTSE

    8,232.04
    -30.71 (-0.37%)
     
  • NIKKEI 225

    38,453.46
    -384.00 (-0.99%)
     
  • CAD/EUR

    0.6715
    -0.0001 (-0.01%)
     

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Chemomab Therapeutics
Chemomab Therapeutics

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the Aegis Virtual Conference on May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast live. The registration link to access the live presentation is included below and is also available at the Events section of the Chemomab website.

Chemomab Presentation at 2024 Aegis Virtual Conference

Date:

May 7, 2024

Time:

9:00 am ET

Venue:

Virtual

Format:

Live webcast presentation

Registration:

https://us02web.zoom.us/meeting/register/tZMkd-2trzIsHNTrU4RNyTw2dYX2Pqs_t-o8

Information:

info@aegiscap.com

 

 

About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information about Chemomab, visit chemomab.com.

ADVERTISEMENT

Contacts:

Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com